Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.
暂无分享,去创建一个
T. Rüffer | H. Lang | R. Paschke | G. Kaluđerović | M. Korb | G. Ludwig | D. Steinborn | M. Block | Martin Bette
[1] R. Paschke,et al. Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties. , 2012, Journal of inorganic biochemistry.
[2] R. Britto,et al. Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action. , 2010, Journal of inorganic biochemistry.
[3] P. Sadler,et al. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. , 2009, Drug discovery today.
[4] N. Farrell,et al. Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. , 2009, Journal of medicinal chemistry.
[5] Andrew D. Phillips,et al. Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta , 2009 .
[6] M. Jakupec,et al. Water-Soluble Mixed-Ligand Ruthenium(II) and Osmium(II) Arene Complexes with High Antiproliferative Activity , 2008 .
[7] Anna F. A. Peacock,et al. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. , 2008, Chemistry, an Asian journal.
[8] Michael Groessl,et al. In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. , 2008, Chemistry.
[9] P. Sadler,et al. Catalytic organometallic anticancer complexes , 2008, Proceedings of the National Academy of Sciences.
[10] A. Spek,et al. Ruthenium(III) chloride complex with a tridentate bis(arylimino)pyridine ligand: synthesis, spectra, X-ray structure, 9-ethylguanine binding pattern, and in vitro cytotoxicity. , 2008, Inorganic chemistry.
[11] N. V. Stolyarova,et al. Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds , 2008 .
[12] P. Dyson,et al. The "complex-in-a-complex" cations [(acac)2M subset Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: A trojan horse for cancer cells. , 2008, Angewandte Chemie.
[13] P. Dyson,et al. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. , 2008, International journal of oncology.
[14] J. Reedijk,et al. Synthesis, characterization and DNA binding properties of oligopyridine-ruthenium(II)-amino acid conjugates. , 2007, Journal of inorganic biochemistry.
[15] M. Jakupec,et al. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.
[16] M. Jakupec,et al. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. , 2006, Dalton transactions.
[17] B. Marian,et al. KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview. , 2005, International journal of clinical pharmacology and therapeutics.
[18] M. Jakupec,et al. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. , 2005, Current medicinal chemistry.
[19] P. Dyson,et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. , 2005, Journal of medicinal chemistry.
[20] G. Sava,et al. Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse , 1994, Clinical & Experimental Metastasis.
[21] J. Schellens,et al. A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.
[22] J. Cummings,et al. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer , 2002, British Journal of Cancer.
[23] J. Cummings,et al. Inhibition of cancer cell growth by ruthenium(II) arene complexes. , 2001, Journal of medicinal chemistry.
[24] C. S. Allardyce,et al. [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells , 2001 .
[25] G. Sava,et al. Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. , 2000, Pharmacology & toxicology.
[26] A. Bergamo,et al. Ruthenium-based compounds and tumour growth control (review). , 2000, International journal of oncology.
[27] C. Giandomenico,et al. Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.
[28] M J Clarke,et al. Non-platinum chemotherapeutic metallopharmaceuticals. , 1999, Chemical reviews.
[29] P. Sadler,et al. Metals in Medicine. , 1999, Angewandte Chemie.
[30] G. Chu,et al. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. , 1994, The Journal of biological chemistry.
[31] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[32] M. Clarke,et al. Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components. , 1980, Journal of inorganic biochemistry.
[33] J. Trosko,et al. Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.
[34] BARNETT ROSENBERG,et al. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.